X0206 3 2018-06-19 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001742485 Kumar Neil C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104 1 1 1 0 Chief Executive Officer Series Seed Convertible Preferred Stock Common Stock 15347219 I See footnote Series B Convertible Preferred Stock Common Stock 3081813 I See footnote Convertible Preferred Warrant (right to buy) 10.8348 2021-02-21 Series B Preferred Stock 332262 I See footnote The convertible preferred stock will automatically convert into the Issuer's Common Stock on a 1-to-1.196 basis upon the closing of the Issuer's initial public offering and has no expiration date. The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein. Immediately prior to completion of the Issuer's initial public offering, the warrants will automatically be exercised for shares of Series B Preferred Stock and such shares acquired will automatically be converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock. Exhibit 24.1 - Power of Attorney /s/ Franco Valle, Attorney-in-Fact 2018-06-19